RAF inhibitors for treating low-grade gliomas

JP2023548600A5Active Publication Date: 2024-11-12DAY ONE BIOPHARMACEUTICALS INC +2
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023527333
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-01-15
Filing Date
2021-11-05
Publication Date
2024-11-12
Estimated Expiration
2041-11-05

AI Technical Summary

Benefits of technology

を有する組成物の任意の毒性または有害な効果を超える量である。

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

Described herein are methods and compositions for treating glioma (e.g., pediatric low-grade glioma). In some embodiments, described herein are methods for treating pediatric low-grade glioma, the methods comprising administering to a subject in need thereof (R)-2-(1-(6-amino-5-chloropyrimidine-4-carboxamido)ethyl)-N-(5-chloro-4-(trifluoromethyl)pyridin-2-yl)thiazole-5-carboxamide (Compound A), or a pharmaceutically acceptable salt thereof. In some embodiments, Compound A, or a pharmaceutically acceptable salt thereof, is administered at a dose of about 400 mg / m per week. 2 ~about 600mg / m 2 of Compound A. In some embodiments, the subject is under 20 years of age.
Need to check novelty before this filing date? Find Prior Art

Claims

1. A composition for use in treating low grade glioma (LGG) in a subject in need thereof, comprising a compound which is (R)-2-(1-(6-amino-5-chloropyrimidine-4-carboxamido)ethyl)-N-(5-chloro-4-(trifluoromethyl)pyridin-2-yl)thiazole-5-carboxamide (Compound A), or a pharma- ceutically acceptable salt thereof, The initial dose of Compound A or a pharma- ceutical acceptable salt thereof is about 350 mg / m per week. 2 ~About 450mg / m 2 is equal to compound A of wherein the subject is under 20 years of age.

2. The initial dose of Compound A or a pharma- ceutically acceptable salt thereof is about 380 mg / m per week. 2 The composition for use according to claim 1, wherein the compound A is equal to:

3. The initial dose of Compound A or a pharma- ceutical acceptable salt thereof is about 420 mg / m per week. 2 The composition for use according to claim 1, wherein the compound A is equal to:

4. A composition for use according to any one of claims 1 to 3, characterized in that the composition is administered in combination with one or more therapeutic agents for treating a skin-related condition or disorder.

5. The composition for use according to any one of claims 1 to 3, wherein the LGG is radiographically recurrent disease or radiographically progressive disease.

6. The composition for use according to any one of claims 1 to 3, wherein the LGG is recurrent LGG or refractory LGG.

7. The composition for use according to any one of claims 1 to 3, wherein the LGG has an activating BRAF alteration or BRAF mutation.

8. The composition for use according to any one of claims 1 to 3, wherein the compound A or a pharma- ceutically acceptable salt thereof is (R)-2-(1-(6-amino-5-chloropyrimidine-4-carboxamido)ethyl)-N-(5-chloro-4-(trifluoromethyl)pyridin-2-yl)thiazole-5-carboxamide.

9. The composition for use according to any one of claims 1 to 3, wherein the composition is a liquid suspension.

10. The composition for use according to any one of claims 1 to 3, wherein the composition is a tablet.

11. The composition for use according to any one of claims 1 to 3, characterized in that the composition is administered as a single dose per week.

12. The composition for use according to any one of claims 1 to 3, characterized in that the composition is administered for a period of at least 24 months.

13. The composition for use according to any one of claims 1 to 3, wherein the LGG has a BRAF mutation.

14. The composition for use according to any one of claims 1 to 3, wherein the subject has undergone one or more treatments selected from surgery, radiation, and chemotherapy prior to administering the composition, or the subject has undergone a complete or partial resection prior to administering the composition.

15. The composition for use according to any one of claims 1 to 3, characterized in that the composition is administered at a maximum dose of 600 mg of compound A or a pharma- ceutically acceptable salt thereof.

16. A composition for use in a method for treating pediatric low grade glioma (pLGG) in a subject in need thereof, comprising a compound which is (R)-2-(1-(6-amino-5-chloropyrimidine-4-carboxamido)ethyl)-N-(5-chloro-4-(trifluoromethyl)pyridin-2-yl)thiazole-5-carboxamide (Compound A), or a pharma- ceutically acceptable salt thereof, The method includes administering the composition to the subject; wherein said initial dose of Compound A or a pharma- ceutically acceptable salt thereof is equivalent to about 350 mg / m2 to about 450 mg / m2 of Compound A per week; wherein the subject is between about 6 months and about 25 years of age. composition.